| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1University of Ljubljana, Department of Biology, Vecna pot 111, 1000 Ljubljana, Slovenia 2,8Unité de Génétique Moléculaire Bactérienne2 and Unité des Toxines Microbiennes8, Institut Pasteur, Paris, France 3Centre for Molecular Microbiology and Infection, Imperial College, London, UK 4Hines VA Hospital, Hospital/151 Fifth Avenue & Roosevelt Road, Hines, IL 60141, USA 5Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA 6Institute of Toxicology, Hannover Medical School, Hannover, Germany 7TechLab Inc., Blacksburg, VA, USA 9Australian Bacterial Pathogenesis Program, Department of Microbiology, Monash University, Victoria 3800, Australia 10Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA 11Microbiology and Tumorbiology Center, Karolinska Institute, Stockholm, Sweden 12London School of Hygiene and Tropical Medicine, University of London, UK 13Institute of Medical Microbiology and Hygiene, Johannes Gutenberg University of Mainz, D-55101 Mainz, Germany
Correspondence Maja Rupnik maja.rupnik{at}bf.uni-lj.si
Received July 3, 2004
Accepted August 6, 2004
Several different nomenclatures have been applied to the Clostridium difficile toxins and their associated genes. This paper summarizes the new nomenclature that has been agreed to by the research groups currently active in the field. The revised nomenclature includes C. difficile toxins and other related large clostridial toxins produced by Clostridium sordellii and Clostridium novyi, and corresponding toxin genes, as well as toxin production types of C. difficile strains.
Abbreviation: LCT, large clostridial toxin.
This article has been cited by other articles:
|
|
 |
|
  E. Kokkotou, A. C. Moss, A. Michos, D. Espinoza, J. W. Cloud, N. Mustafa, M. O'Brien, C. Pothoulakis, and C. P. Kelly Comparative Efficacies of Rifaximin and Vancomycin for Treatment of Clostridium difficile-Associated Diarrhea and Prevention of Disease Recurrence in Hamsters Antimicrob. Agents Chemother., March 1, 2008; 52(3): 1121 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Amimoto, T. Noro, E. Oishi, and M. Shimizu A novel toxin homologous to large clostridial cytotoxins found in culture supernatant of Clostridium perfringens type C Microbiology, April 1, 2007; 153(4): 1198 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Goh, P. F. Ong, K. P. Song, T. V. Riley, and B. J. Chang The complete genome sequence of Clostridium difficile phage {phi}C2 and comparisons to {phi}CD119 and inducible prophages of CD630 Microbiology, March 1, 2007; 153(3): 676 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mani, B. Dupuy, and A. L. Sonenshein Isolation of RNA Polymerase from Clostridium difficile and Characterization of Glutamate Dehydrogenase and rRNA Gene Promoters In Vitro and In Vivo J. Bacteriol., January 1, 2006; 188(1): 96 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhao, F. Kong, and G. L. Gilbert Reverse Line Blot Assay for Direct Identification of Seven Streptococcus agalactiae Major Surface Protein Antigen Genes Clin. Vaccine Immunol., January 1, 2006; 13(1): 145 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. S. Ho, A. Greco, M. Rupnik, and K. K.-S. Ng Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A PNAS, December 20, 2005; 102(51): 18373 - 18378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. R Poxton Clostridium difficile J. Med. Microbiol., February 1, 2005; 54(2): 97 - 100. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | J MED MICROBIOL | MICROBIOLOGY | J GEN VIROL | ALL SGM JOURNALS |
